Fusobacterium nucleatum enhances the efficacy of PD-L1 blockade in colorectal cancer

• Published in: Signal transduction and targeted therapy Vol. 6; no. 1; pp. 398 - 10
• Main Authors: Gao, Yaohui, Bi, Dexi, Xie, Ruting, Li, Man, Guo, Jing, Liu, Hu, Guo, Xianling, Fang, Juemin, Ding, Tingting, Zhu, Huiyuan, Cao, Yuan, Xing, Meichun, Zheng, Jiayi, Xu, Qing, Xu, Qian, Wei, Qing, Qin, Huanlong
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 19.11.2021; Nature Publishing Group
• Subjects: 692/53/2422; 692/699/67/1504; Antitumor activity; Cancer; Cancer Research; CD8 antigen; Cell Biology; Colorectal cancer; Colorectal carcinoma; Fusobacterium nucleatum; Immune checkpoint; Immune response; Immunotherapy; Internal Medicine; Lymphocytes; Medicine; Medicine & Public Health; Oncology; Organoids; Pathology; Patients; PD-1 protein; PD-L1 protein; Supplements; Tumor-infiltrating lymphocytes; γ-Interferon

Given that only a subset of patients with colorectal cancer (CRC) benefit from immune checkpoint therapy, efforts are ongoing to identify markers that predict immunotherapeutic response. Increasing evidence suggests that microbes influence the efficacy of cancer therapies. Fusobacterium nucleatum in...